Literature DB >> 32779328

Severe cutaneous adverse drug reactions: Incidence, clinical patterns, causative drugs and modalities of treatment in Assiut University Hospital, Upper Egypt.

Doaa A E Abou-Taleb1, Ahmed M El-Sayed2, Ayad A Ghabesha3, Sahar B Hassan4.   

Abstract

Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and overlap SJS/TEN are life-threatening diseases that are most frequently caused by drugs. Much debate remains about the role of systemic corticosteroids (SCs) in their treatment. Our aim to determine the incidence, causative drugs, the role and side effects of SCs in severe cutaneous adverse reactions (SCARs), in Assiut University Hospital (AUH). Patients This study was conducted in Department of Dermatology at AUH, from 2012 to 2017. All patients with SJS, overlap SJS/TEN and TEN admitted during this period were included in the study. Eighty-three patients with SCARs were included in this study. The most common type was SJS (67.5%). The incidence ranged from 1.7% in 2012 to 7.7% in 2017. Carbamazepine, valproic acid, lamotrigine, diclofenac sodium, and flucloxacillin-amoxicillin were the most common causative drugs. The most common side effects of SCs were peptic ulcer (55.5%) and hypertension (51.8%). The mortality rate in patients treated with SCs was 100% in TEN, 33.3% in overlap SJS/TEN and 16.3% in SJS. The patients of SCARs must be aware of the causative drugs and must never be re-administered. SCs in treatment of SCARs may increase the complications and the mortality rate.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  Stevens-Johnson syndrome; severe cutaneous adverse reactions; systemic corticosteroids; toxic epidermal necrolysis

Mesh:

Substances:

Year:  2020        PMID: 32779328     DOI: 10.1111/dth.14176

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  Intravenous Immunoglobulin Combined With Corticosteroids for the Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Propensity-Matched Retrospective Study in China.

Authors:  Lu Yang; Yan-Hong Shou; Feng Li; Xiao-Hua Zhu; Yong-Sheng Yang; Jin-Hua Xu
Journal:  Front Pharmacol       Date:  2022-01-18       Impact factor: 5.810

Review 2.  Current Perspectives on Severe Drug Eruption.

Authors:  Jingzhan Zhang; Zixian Lei; Chen Xu; Juan Zhao; Xiaojing Kang
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-17       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.